Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.
Neuren Pharmaceuticals Limited announced an update on its ongoing buy-back program, reporting a total of 3,837,460 securities bought back prior to the previous day, with an additional 33,732 securities repurchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company’s primary products are aimed at addressing unmet medical needs in this specialized market.
Average Trading Volume: 741,578
Technical Sentiment Signal: Buy
Current Market Cap: A$1.74B
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.